We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Trillium Therapeutics Inc | NASDAQ:TRIL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.44 | 20.33 | 18.30 | 0 | 01:00:00 |
“Coming off an R&D Day last week, we are very excited to have launched a new chapter in Trillium’s evolution,” said Jan Skvarka, Trillium’s President and CEO. “Building on a robust foundation anchored in a demonstrated monotherapy proof of concept of TTI-622 and TTI-621 in multiple lymphoma indications, we have initiated an ambitious Phase 1b/2 program in nine patient settings across hematologic and solid tumor cancers. With a major transformation program that touched literally every aspect of our identity completed in 2020, and approximately $276 million in cash, we are very well positioned to execute the recently initiated Phase 1b/2 program, and generate a robust flow of new data over the next couple of years.”
First Quarter 2021 Financial Results
About Trillium Therapeutics
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-622 and TTI-621, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.
For more information visit: www.trilliumtherapeutics.com
Caution Regarding Forward-Looking Information
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable United States federal securities laws and forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The use of words such as “may,” “will,” “could,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions can be used to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, express or implied statements regarding the therapeutic potential and monotherapy activity of our programs, our clinical development plans and our expectations with respect to initiating Phase 1b/2 studies in hematological and solid tumor malignancies, and the expected timing of the release of further data on Trillium’s TTI-622 and TTI-621 studies. With respect to the forward-looking statements contained in this press release, Trillium has made numerous assumptions regarding, among other things: the impact of the COVID-19 pandemic on its operations, the effectiveness and timeliness of preclinical and clinical trials; and the completeness, accuracy and usefulness of the data. While Trillium considers these assumptions to be reasonable, these assumptions are inherently subject to significant scientific, business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors that could cause Trillium’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained in this press release. A discussion of risks and uncertainties facing Trillium appears in Trillium’s Annual Report on Form 10-K for the year ended December 31, 2020, with the U.S. Securities Exchange Commission, each as updated by Trillium’s continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Trillium disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
Trillium Therapeutics Inc.Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)(amounts in thousands, except share and per share data) | |||||||
Three months endedMarch 31, 2021 | Three months endedMarch 31, 2020 | ||||||
Operating expenses | |||||||
Research and development expenses | $ | 5,924 | $ | 4,988 | |||
General and administrative expenses | 5,390 | 11,675 | |||||
Total operating expenses | 11,314 | 16,663 | |||||
Operating loss | (11,314 | ) | (16,663 | ) | |||
Other income (expense) | |||||||
Interest income, net | 529 | 412 | |||||
Net foreign currency loss | (35 | ) | (24 | ) | |||
Total other income, net | 494 | 388 | |||||
Net loss before income taxes | (10,820 | ) | (16,275 | ) | |||
Income tax expense | 42 | 23 | |||||
Net loss and comprehensive loss | (10,862 | ) | (16,298 | ) | |||
Net loss per share, basic and diluted | (0.11 | ) | (0.25 | ) | |||
Weighted average number of common shares used in computing net loss per share, basic and diluted | 103,004,158 | 65,522,274 |
Trillium Therapeutics Inc.Selected Condensed Consolidated Balance Sheet Data(unaudited)(amounts in thousands) | |||||
March 31, 2021 | December 31, 2020 | ||||
Cash and cash equivalents, and marketable securities | $ | 275,652 | $ | 291,165 | |
Total assets | 288,288 | 300,822 | |||
Total liabilities | 15,303 | 21,975 | |||
Total stockholders’ equity | 272,985 | 278,847 |
Company Contact:Rosemary HarrisonSVP, Corporate Development and StrategyTrillium Therapeutics Inc. 416-595-0627 x225investors@trilliumtherapeutics.com www.trilliumtherapeutics.com
Media Relations:Mike BeyerSam Brown Inc.312-961-2502mikebeyer@sambrown.com
1 Year Trillium Therapeutics Chart |
1 Month Trillium Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions